Cited by 228Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver Diseases and Immunity

The DOI matches its Crossref record; 541 of the 545 references it cites were found in a registry or an index.

Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management

Open access

Marjot, Thomas, Moolla, Ahmad, Cobbold, Jeremy F, Hodson, Leanne, Tomlinson, Jeremy W·2020·Endocrine Reviews

Open this paper in CoChat — free account Open PDF

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It is highly prevalent and is associated with significant adverse outcomes both through liver-specific morbidity and mortality but, perhaps more important, through adverse cardiovascular and metabolic outcomes. It is closely associated with type 2 diabetes and obesity, and both of these conditions drive progressive disease toward the more advanced stages. The mechanisms that govern hepatic lipid accumulation and the predisposition to inflammation and fibrosis are still not fully understood but reflect a complex interplay between metabolic target tissues including adipose and skeletal muscle, and immune and inflammatory cells. The ability to make an accurate assessment of disease stage (that relates to clinical outcome) can also be challenging. While liver biopsy is still regarded as the gold-standard investigative tool, there is an extensive literature on the search for novel noninvasive biomarkers and imaging modalities that aim to accurately reflect the stage of underlying disease. Finally, although no therapies are currently licensed for the treatment of NAFLD, there are interventions that appear to have proven efficacy in randomized controlled trials as well as an extensive emerging therapeutic landscape of new agents that target many of the fundamental pathophysiological processes that drive NAFLD. It is highly likely that over the next few years, new treatments with a specific license for the treatment of NAFLD will become available.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1210/endrev/bnz009

Cites

541 of 541 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–400 of 541

Mediterranean diet and nonalcoholic fatty liver disease
Anania, C., Perla, F. M., Olivero, F., Pacifico, L., & Chiesa, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2083 · Cited by 353
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
Leung, J. C., Loong, T. C., Wei, J. L., Wong, G. L., Chan, A. W. H., Choi, P. C., Shu, S. S., Chim, A. M., Chan, H. L., & Wong, V. W. (2016) · Hepatology · doi:10.1002/hep.28697 · Cited by 348
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
Mantovani, A., Zaza, G., Byrne, C. D., Lonardo, A., Zoppini, G., Bonora, E., & Targher, G. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.003 · Cited by 348
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Liver Adenine Nucleotides: Fructose-Induced Depletion and Its Effect on Protein Synthesis
Mäenpää, P. H., Raivio, K. O., & Kekomäki, M. P. (1968) · Science · doi:10.1126/science.161.3847.1253 · Cited by 344
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340
Intermittent hypoxia induces hyperlipidemia in lean mice
Li, J., Thorne, L. N., Punjabi, N. M., Sun, C.-K., Schwartz, A. R., Smith, P. L., Marino, R. L., Rodriguez, A., Hubbard, W. C., O’Donnell, C. P., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000183879.60089.a9 · Cited by 335
FRUCTOSE-INDUCED HYPERURICÆMIA
Stirpe, F., Corte, E. D., Bonetti, E., Abbondanza, A., Abbati, A., & Stefano, F. D. (1970) · The Lancet · doi:10.1016/s0140-6736(70)92269-5 · Cited by 331
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Cui, J. Y., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 330
Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review
Desai, A., Sandhu, S., Lai, J., & Sandhu, D. S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i1.1 · Cited by 328
Regulation of Liver Metabolism by Autophagy
Madrigal‐Matute, J., & Cuervo, A. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.09.042 · Cited by 319
Predictive value of ALT levels for non‐alcoholic steatohepatitis ( NASH ) and advanced fibrosis in non‐alcoholic fatty liver disease ( NAFLD )
Verma, S. S., Jensen, D. M., Hart, J. A. L., & Mohanty, S. R. (2013) · Liver International · doi:10.1111/liv.12226 · Cited by 319
Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy
Wei, J. L., Leung, J. C., Loong, T. C., Wong, G. L., Yeung, D. K., Chan, R., Chan, H. L., Chim, A. M., Woo, J., Chu, C. W., et al. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.235 · Cited by 317
17‐Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease
Ma, Y., Belyaeva, O. V., Brown, P. M., Fujita, K., Valles, K., Karki, S., de Boer, Y. S., Koh, C., Chen, Y., Du, X., et al. (2018) · Hepatology · doi:10.1002/hep.30350 · Cited by 317
Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
Dowman, J. K., Tomlinson, J., & Newsome, P. N. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 316
Association of Coffee and Caffeine Consumption With Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Degree of Hepatic Fibrosis
Molloy, J. W., Calcagno, C. J., Williams, C. D., Jones, F. J., Torres, D. M., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24731 · Cited by 316
Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease
Sullivan, S. A., Kirk, E. P., Mittendorfer, B., Patterson, B. W., & Klein, S. (2011) · Hepatology · doi:10.1002/hep.25548 · Cited by 313
Effect of aerobic exercise training dose on liver fat and visceral adiposity
Keating, S. E., Hackett, D. A., Parker, H. M., O’Connor, H. T., Gerofi, J. A., Sainsbury, A., Baker, M. K., Chuter, V. H., Caterson, I. D., George, J., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.022 · Cited by 313
Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312
Association between non-alcoholic fatty liver disease and cancer incidence rate.
Kim, G.-A., Lee, H.-C., Choe, J., Kim, M.-J., Lee, M. J., Chang, H.-S., Bae, I. Y., Kim, H., An, J., Shim, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.012 · Cited by 311
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial
Sanyal, A. J., Abdelmalek, M. F., Suzuki, A., Cummings, O. W., & Chojkier, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.046 · Cited by 309
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stal, P. I., Hultcrantz, R. W., & Kechagias, S. (2017) · Hepatology Communications · doi:10.1002/hep4.1124 · Cited by 309
Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects
Haufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307
Natural killer cells in liver disease
Tian, Z., Chen, Y., & Gao, B. (2012) · Hepatology · doi:10.1002/hep.26115 · Cited by 306
The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation
BasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
Liver transplantation: past, present and future
Zarrinpar, A., & Busuttil, R. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.88 · Cited by 299
Prevalence of generalized & abdominal obesity in urban & rural India- the ICMR - INDIAB Study (Phase-I) [ICMR - INDIAB-3]
Mohan, V., Pradeepa, R., Anjana, R., Joshi, S., Bhansali, A., Deepa, M., Joshi, P., Dhandania, V., Madhu, S. V., Rao, P., et al. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.164234 · Cited by 299
Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials
Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.-M., Rizkalla, S., Schrezenmeir, J., & Clément, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2017-017995 · Cited by 299
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
Armstrong, M. J., Houlihan, D. D., Bentham, L., Shaw, J. C., Cramb, R., Olliff, S. P., Gill, P. S., Neuberger, J., Lilford, R. J., & Newsome, P. N. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.020 · Cited by 298
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis
Rensen, S. S., Slaats, Y., Nijhuis, J., Jans, A., Bieghs, V., Driessen, A., Malle, E., Greve, J. W., & Buurman, W. A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080999 · Cited by 290
Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes
Choi, Y.-J., Shin, H.-S., Choi, H. S., Park, J.-W., Jo, I., Oh, E., Lee, K.-Y., Lee, B., Johnson, R. J., & Kang, D. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.98 · Cited by 290
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 290
Mechanisms of cardiac dysfunction in obstructive sleep apnea
Baguet, J.-P., Barone‐Rochette, G., Tamisier, R., Levy, P. A., & Pépin, J. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.141 · Cited by 285
Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285
The Evolution of Metabolic/Bariatric Surgery
Buchwald, H. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1354-3 · Cited by 285
Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
Singal, A. K., Guturu, P., Hmoud, B., Kuo, Y.-F., Salameh, H., & Wiesner, R. H. (2013) · Transplantation · doi:10.1097/tp.0b013e31827afb3a · Cited by 278
Hepatic MRI for Fat Quantitation
Fishbein, M. H., Castro, F., Cheruku, S. M., Jain, S., Webb, B., Gleason, T., & Stevens, W. R. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200508000-00012 · Cited by 277
Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis
Gu, J., Liu, S., Du, S., Zhang, Q., Xiao, J., Dong, Q., & Xin, Y. (2019) · European Radiology · doi:10.1007/s00330-019-06072-4 · Cited by 276
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
Safadi, R., Konikoff, F. M., Mahamid, M., Zelber‐Sagi, S., Halpern, M., Gilat, T., Oren, R., Safadi, R., Konikoff, F. M., Hershkovitz, A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.038 · Cited by 275
Variant in the glucokinase regulatory protein ( GCKR ) gene is associated with fatty liver in obese children and adolescents
Santoro, N., Zhang, C. K., Zhao, H., PAKSTIS, A. J., Kim, G., Kursawe, R., Dykas, D. J., Bale, A. E., Giannini, C., Pierpont, B. M., et al. (2011) · Hepatology · doi:10.1002/hep.24806 · Cited by 272
Effects of Identical Weight Loss on Body Composition and Features of Insulin Resistance in Obese Women With High and Low Liver Fat Content
Tiikkainen, M., Bergholm, R., Vehkavaara, S., Rissanen, A., Häkkinen, A.-M., Tamminen, M., Teramo, K., & Yki-Järvinen, H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.701 · Cited by 271
Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH
Sutti, S., Jindal, A., Locatelli, I., Vacchiano, M., Gigliotti, L., Bozzola, C., & Albano, E. (2014) · Hepatology · doi:10.1002/hep.26749 · Cited by 270
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
Dai, W., Ye, L., Liu, A., Wen, S. W., Deng, J., Wu, X. Y., & Lai, Z. (2017) · Medicine · doi:10.1097/md.0000000000008179 · Cited by 268
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L. A., & Vettor, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01821 · Cited by 266
Adiponectin, a key adipokine in obesity related liver diseases.
Buechler, C., Wanninger, J., & Neumeier, M. (2011) · PubMed · doi:10.3748/wjg.v17.i23.2801 · Cited by 264
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Trauner, M. A., Gulamhusein, A. F., Hameed, B., Caldwell, S. H., Shiffman, M. L., Landis, C. S., Eksteen, B., Agarwal, K., Muir, A. J., Rushbrook, S., et al. (2019) · Hepatology · doi:10.1002/hep.30509 · Cited by 263
Chronic intermittent hypoxia predisposes to liver injury†
Savransky, V., Nanayakkara, A., Vivero, A., Li, J., Bevans‐Fonti, S., Smith, P. L., Torbenson, M. S., & Polotsky, V. Y. (2007) · Hepatology · doi:10.1002/hep.21593 · Cited by 262
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262
Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study
Koehler, E. M., Schouten, J. N. L., Hansen, B. E., van Rooij, F. J. A., Albert Hofman, D., Stricker, B. H. C., & Janssen, H. L. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.028 · Cited by 261
The Western Dietary Pattern Is Prospectively Associated With Nonalcoholic Fatty Liver Disease in Adolescence
Oddy, W. H., Herbison, C. E., Jacoby, P., Ambrosini, G. L., O’Sullivan, T. A., Ayonrinde, O. T., Olynyk, J. K., Black, L. J., Beilin, L. J., Mori, T. A., et al. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.95 · Cited by 259
Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V., Hardies, J., & Cusi, K. J. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 258
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., Luca, L. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 257
The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients
Latva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253
FRUCTOSE-INDUCED HYPERURICÆMIA
Perheentupa, J., & Raivio, K. (1967) · The Lancet · doi:10.1016/s0140-6736(67)90494-1 · Cited by 251
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250
Self-citation
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
Athyros, V. G., Mikhailidis, D. P., Didangelos, T., Γιουλεμέ, Ό., Liberopoulos, E. N., Karagiannis, A. I., Kakafika, A. I., Τζιόμαλος, Κ., Burroughs, A. K., & Elisaf, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104696 · Cited by 248
Patatin-Like Phospholipase Domain-Containing 3/Adiponutrin Deficiency in Mice Is Not Associated with Fatty Liver Disease†,‡
Chen, W., Chang, B. H., Li, L., & Chan, L. (2010) · Hepatology · doi:10.1002/hep.23812 · Cited by 246
Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens
Gutiérrez-Grobe, Y., Ponciano‐Rodríguez, G., Ramos, M. H., Uribe, M., & Méndez‐Sánchez, N. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31616-3 · Cited by 246
Change in Liver Size and Fat Content after Treatment with Optifast® Very Low Calorie Diet
Lewis, M., Phillips, M., Slavotinek, J., Kow, L., Thompson, C. H., & Toouli, J. (2006) · Obesity Surgery · doi:10.1381/096089206777346682 · Cited by 239
Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 238
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes
Cholankeril, G. T., Wong, R. J., Hu, M., Perumpail, R. B., Yoo, E. R., Puri, P., Younossi, Z. M., Harrison, S. A., & Ahmed, A. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4684-x · Cited by 236
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235
NASH in lean individuals
Younes, R., & Bugianesi, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1677517 · Cited by 235
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
Kelly, M. J., Pietranico-Cole, S., Larigan, J. D., Haynes, N.-E., Reynolds, C. H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.-S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4019299 · Cited by 231
A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial
Nelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c392e · Cited by 230
Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients
Sookoian, S., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14112 · Cited by 230
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity
Fracanzani, A. L., Petta, S., Lombardi, R., Pisano, G., Russello, M., Consonni, D., Marco, V. D., Cammà, C., Mensi, L., Dongiovanni, P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.045 · Cited by 230
Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients
Bozzetto, L., Prinster, A., Annuzzi, G., Costagliola, L., Mangione, A., Vitelli, A., Mazzarella, R., Longobardo, M., Mancini, M., Vigorito, C., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0033 · Cited by 227
Impact of coffee on liver diseases: a systematic review
Saab, S., Mallam, D., Cox, G. A., & Tong, M. J. (2013) · Liver International · doi:10.1111/liv.12304 · Cited by 226
The Roles of Leptin and Adiponectin
Ding, X., Saxena, N. K., Lin, S., Xu, A., Srinivasan, S., & Anania, F. A. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62476-5 · Cited by 225
Incidence and natural course of fatty liver in the general population: The Dionysos study
Bedogni, G., Miglioli, L., Masutti, F., Castiglione, A., Crocè, L. S., Tiribelli, C., & Bellentani, S. (2007) · Hepatology · doi:10.1002/hep.21827 · Cited by 224
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022577 · Cited by 222
CKD and Nonalcoholic Fatty Liver Disease
Targher, G., Chonchol, M. B., & Byrne, C. D. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.05.019 · Cited by 221
Expression of fatty acid synthase in nonalcoholic fatty liver disease
Dorn, C., Riener, M., Kirovski, G., Saugspier, M., Steib, K., Weiß, T. S., Gäbele, E., Kristiansen, G., Hartmann, A., & Hellerbrand, C. (2010) · PubMed Central · doi:10.5283/epub.37047 · Cited by 217
High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial
Cassidy, S., Thoma, C., Hallsworth, K., Parikh, J. D., Hollingsworth, K. G., Taylor, R., Jakovljević, D. G., & Trenell, M. I. (2015) · Diabetologia · doi:10.1007/s00125-015-3741-2 · Cited by 217
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Relationship of sitting time and physical activity with non-alcoholic fatty liver disease
Ryu, S., Chang, Y., Jung, H. S., Yun, K. E., Kwon, M., Choi, Y., Kim, C., Cho, J., Suh, B.-S., Cho, Y. K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.010 · Cited by 215
Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver
Savransky, V., Bevans‐Fonti, S., Nanayakkara, A., Li, J., Smith, P. L., Torbenson, M. S., & Polotsky, V. Y. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00145.2007 · Cited by 215
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
Weston, C. J., Shepherd, E. L., Claridge, L. C., Rantakari, P., Curbishley, S. M., Tomlinson, J., Hübscher, S. G., Reynolds, G. M., Aalto, K., Anstee, Q. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73722 · Cited by 214
Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia–reperfusion injury
Serviddio, G., Bellanti, F., Tamborra, R., Rollo, T., Capitanio, N., Romano, A. D., Sastre, J., Vendemiale, G., & Altomare, E. (2008) · Gut · doi:10.1136/gut.2007.147496 · Cited by 214
Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans
Sevastianova, K., Santos, A., Kotronen, A., Hakkarainen, A., Makkonen, J., Silander, K., Peltonen, M., Romeo, S., Lundbom, J., Lundbom, N., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.038695 · Cited by 211
Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease
Chang, Y., Jung, H. S., Cho, J., Zhang, Y., Yun, K. E., Lazo, M., Pastor‐Barriuso, R., Ahn, J., Kim, C., Rampal, S., et al. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.178 · Cited by 209
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease
Klair, J. S., Yang, J. D., Abdelmalek, M. F., Guy, C. D., Gill, R. M., Yates, K. P., Ünalp–Arida, A., Lavine, J. E., Clark, J. M., Diehl, A. M., et al. (2016) · Hepatology · doi:10.1002/hep.28514 · Cited by 207
Dual PPAR α/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Jain, M. R., Giri, S. R., Bhoi, B., Trivedi, C. J., Rath, A., Rathod, R., Ranvir, R. K., Kadam, S. B., Patel, H., Swain, P. K., et al. (2017) · Liver International · doi:10.1111/liv.13634 · Cited by 207
Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption
Davis, J. N., Lê, K., Walker, R. W., Vikman, S., Spruijt‐Metz, D., Weigensberg, M. J., Allayee, H., & Goran, M. I. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.30185 · Cited by 206
Prevalence of nonalcoholic fatty liver disease in mainland of C hina: A meta‐analysis of published studies
Li, Z.-Z., Xue, J., Chen, P., Chen, L., Yan, S., & Liu, L. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12428 · Cited by 205
Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis
Wang, X., Li, J., Riaz, D., Shi, G., Liu, C., & Dai, Y. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.023 · Cited by 205
Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: A systematic review from sham CPAP randomized controlled trials
Jullian‐Desayes, I., Joyeux‐Faure, M., Tamisier, R., Launois, S. H., Borel, A., Levy, P. A., & Pépin, J. (2014) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.07.004 · Cited by 205
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
Hyogo, H., Tazuma, S., Arihiro, K., Iwamoto, K., Nabeshima, Y., Inoue, M., Ishitobi, T., Nonaka, M., & Chayama, K. (2008) · Metabolism · doi:10.1016/j.metabol.2008.07.030 · Cited by 205
Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects
Kechagias, S., Ernersson, Å., Dahlqvist, O. L., Lundberg, P., Lindström, T., Nyström, F. H., & for the Fast Food Study Group (2008) · Gut · doi:10.1136/gut.2007.131797 · Cited by 205
Liver transplantation at the extremes of the body mass index
Dick, A. A. S., Spitzer, A. L., Seifert, C. F., Deckert, A., Carithers, R. L., Reyes, J. D., & Perkins, J. D. (2009) · Liver Transplantation · doi:10.1002/lt.21785 · Cited by 204
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
Bruno, S., Maisonneuve, P., Castellana, P., Rotmensz, N., Rossi, S., Maggioni, M., Persico, M., Colombo, A., Monasterolo, F., Casadei-Giunchi, D., et al. (2005) · BMJ · doi:10.1136/bmj.38391.663287.e0 · Cited by 201
Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial
Hallsworth, K., Thoma, C., Hollingsworth, K. G., Cassidy, S., Anstee, Q. M., Day, C. P., & Trenell, M. I. (2015) · Clinical Science · doi:10.1042/cs20150308 · Cited by 201
Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study
Kim, G., Lee, S., Lee, Y., Jun, J. E., Ahn, J., Bae, J. C., Jin, S., Hur, K. Y., Jee, J. H., Lee, M., et al. (2018) · Hepatology · doi:10.1002/hep.30049 · Cited by 198
Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
Pavlides, M., Banerjee, R., Tunnicliffe, E. M., Kelly, M., Collier, J. D., Wang, L. M., Fleming, K. A., Cobbold, J., Robson, M. D., Neubauer, S., et al. (2016) · Liver International · doi:10.1111/liv.13284 · Cited by 197
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study
Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 196
Immune and inflammatory pathways in NASH
Ganz, M., & Szabó, G. (2013) · Hepatology International · doi:10.1007/s12072-013-9468-6 · Cited by 195
Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8
SHANAB, A. A. A., Scully, P., Crosbie, O. M., Buckley, M. J. M., O’Mahony, L., Shanahan, F., Gazareen, S., Murphy, E., & Quigley, E. M. M. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1447-3 · Cited by 195
Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers
Sanna, C., Rosso, C., Marietti, M., & Bugianesi, E. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050717 · Cited by 194
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis
Musso, G., Gambino, R., Biroli, G., Carello, M., Fagà, E., Pacini, G., Michieli, F. D., Cassader, M., Durazzo, M., Rizzetto, M., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00297.x · Cited by 191
Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191
High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate–activated protein kinase
Adachi, M., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.21991 · Cited by 188
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Jf, T., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Li, L., et al. (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.15.7 · Cited by 188
Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Dendritic Cells Limit Fibroinflammatory Injury in Nonalcoholic Steatohepatitis in Mice
Henning, J. R., Graffeo, C. S., Rehman, A., Fallon, N. C., Zambirinis, C. P., Ochi, A., Barilla, R., Jamal, M., Deutsch, M., Greco, S., et al. (2013) · Hepatology · doi:10.1002/hep.26267 · Cited by 185
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J)
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis
Haddad, T. M., Hamdeh, S., Kanmanthareddy, A., & Alla, V. M. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.033 · Cited by 182
Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy
Nishizawa, H., Iguchi, G., Murawaki, A., Fukuoka, H., Hayashi, Y., Kaji, H., Yamamoto, M., Suda, K., Takahashi, M., Seo, Y., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0252 · Cited by 181
Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes
Reinke, C., Bevans‐Fonti, S., Drager, L. F., Shin, M., & Polotsky, V. Y. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00492.2011 · Cited by 179
The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans
Luukkonen, P. K., Zhou, Y., Hyötyläinen, T., Leivonen, M., Arola, J. T., Orho‐Melander, M., Orešič, M., & Yki‐Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.045 · Cited by 178
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea with or without continuous positive airway pressure treatment
Fu, Y., Xia, Y., Yi, H., Xu, H., Guan, J., & Yin, S. (2017) · Sleep and Breathing · doi:10.1007/s11325-016-1393-1 · Cited by 176
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
Harrison, S. A., Marri, S., Chalasani, N., Kohli, R., Aronstein, W. S., Thompson, G. A., Irish, W. D., Miles, M. V., Xanthakos, S. A., Lawitz, E., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13816 · Cited by 176
Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
Laursen, T. L., Hagemann, C. A., Wei, C., Kazankov, K., Thomsen, K. L., Knop, F. K., & Grønbæk, H. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i2.138 · Cited by 176
Skeletal Muscle Insulin Resistance Promotes Increased Hepatic De Novo Lipogenesis, Hyperlipidemia, and Hepatic Steatosis in the Elderly
Flannery, C. A., Dufour, S., Rabøl, R., Shulman, G. I., & Petersen, K. F. (2012) · Diabetes · doi:10.2337/db12-0206 · Cited by 175
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
VanWagner, L. B., Koppe, S., Brunt, E. M., Gottstein, J. H., Gardikiotes, K., Green, R. M., & Rinella, M. E. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31539-x · Cited by 174
Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography
Rockall, A., Sohaib, S., Evans, D., Kaltsas, G., Isidori, A. M., Monson, J., BESSER, G. M., Grossman, A. B., & Reznek, R. H. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490543 · Cited by 174
The dual and opposite role of the TM6SF2‐rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta‐analysis
Pirola, C. J., & Sookoian, S. C. (2015) · Hepatology · doi:10.1002/hep.28142 · Cited by 173
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Sattar, N. A., FITCHETT, D. H., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 173
Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
Gusdon, A. M., Song, K., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 172
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability
Pajvani, U. B., Qiang, L., Kangsamaksin, T., Kitajewski, J., Ginsberg, H. N., & Accili, D. (2013) · Nature Medicine · doi:10.1038/nm.3259 · Cited by 172
Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease
Mitsuyoshi, H., Yasui, K., Harano, Y., Endo, M., Tsuji, K., Minami, M., Itoh, Y., Okanoue, T., & Yoshikawa, T. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00464.x · Cited by 172
The liver diseases of lipodystrophy: The long-term effect of leptin treatment
Zadeh, E. S., Lungu, A. O., Cochran, E. K., Brown, R. J., Ghany, M. G., Heller, T., Kleiner, D. E., & Görden, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.007 · Cited by 169
Intestinal Microbiota and Nonalcoholic Steatohepatitis
Brandl, K., & Schnabl, B. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000349 · Cited by 169
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Ajmera, V. H., Park, C. C., Caussy, C., Singh, S., Hernandez, C., Bettencourt, R., Hooker, J. C., Sy, E. Z., Behling, C. A., Xu, R., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.014 · Cited by 167
Adiponectin, a key adipokine in obesity related liver diseases
Christa, Buechler, Josef, Wanninger, Markus, M. L., & Neumeier (2011) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 167
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 165
Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes
Oral, E. A., Reilly, S. M., Gomez, A. V., Meral, R., Butz, L., Ajluni, N., Chenevert, T. L., Korytnaya, E., Neidert, A., HENCH, R. P., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.006 · Cited by 165
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
Taub, R. A., Chiang, E., Chabot-Blanchet, M., Kelly, M. J., Reeves, R. A., Guertin, M., & Tardif, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.056 · Cited by 164
Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis
Dasarathy, S., Dasarathy, J., Khiyami, A., Yerian, L. M., Hawkins, C., Sargent, R., & McCullough, A. J. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000099 · Cited by 163
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance
Stal, P. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11077 · Cited by 162
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
Kimura, Y., Hyogo, H., Yamagishi, S., Takeuchi, M., Ishitobi, T., Nabeshima, Y., Arihiro, K., & Chayama, K. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0203-y · Cited by 160
Liver fat accumulation is associated with circulating PCSK9
Ruscica, M., Ferri, N., Macchi, C., Meroni, M., Lanti, C., Ricci, C., Maggioni, M., Fracanzani, A. L., Badiali, S., Fargion, S. R., et al. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1188328 · Cited by 160
Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
Kanwal, F., Kramer, J. R., Duan, Z., Yu, X., White, D. L., & El‐Serag, H. B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.010 · Cited by 159
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Belfort, R., Berria, R., Cornell, J. E., & Cusi, K. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1487 · Cited by 159
Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD
Petta, S., Wong, V. W., Cammà, C., Hiriart, J., Wong, G. L., Vergniol, J., Chan, A. W. H., Marco, V. D., Merrouche, W., Chan, H. L., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14219 · Cited by 159
Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis
Xu, R., Tao, A., Zhang, S., Deng, Y., & Chen, G. (2015) · Scientific Reports · doi:10.1038/srep09284 · Cited by 155
A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease
Kim, S., Kwon, H., Park, J., Cho, B., Kim, D., Oh, S., Lee, C. M., & Choi, H.-C. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-69 · Cited by 155
Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial
Zelber-Sagi, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4382 · Cited by 152
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
JOY, T. R., McKenzie, C. A., Tirona, R. G., Summers, K. L., Seney, S. L., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.141 · Cited by 152
Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice
Zhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152
Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance
Baratta, F., Pastori, D., Polimeni, L., Bucci, T., Ceci, F., Calabrese, C. M., Ernesti, I., Pannitteri, G., Violi, F., Angelico, F., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.371 · Cited by 151
Reactive Oxygen Species-generating Mitochondrial DNA Mutation Up-regulates Hypoxia-inducible Factor-1α Gene Transcription via Phosphatidylinositol 3-Kinase-Akt/Protein Kinase C/Histone Deacetylase Pathway
Koshikawa, N., Hayashi, J.-I., Nakagawara, A., & Takenaga, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054221 · Cited by 147
Association Between Variants in or Near PNPLA3, GCKR, and PPP1R3B With Ultrasound-Defined Steatosis Based on Data From the Third National Health and Nutrition Examination Survey
Hernáez, R., McLean, J., Lazo, M., Brancati, F. L., Hirschhorn, J. N., Borecki, I. B., Harris, T. B., Nguyen, T. T., Kamel, I. R., Bonekamp, S., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.011 · Cited by 147
Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis
Yang, D., Hanna, D. L., Usher, J., LoCoco, J., Chaudhari, P., Lenz, H., Setiawan, V. W., & El-Khoueiry, A. B. (2014) · Cancer · doi:10.1002/cncr.28912 · Cited by 144
379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease
Cruz, A. C. D., Bugianesi, E., George, J., Day, C. P., Liaquat, H., Charatcharoenwitthaya, P., Mills, P. R., Dam‐Larsen, S., Bjornsson, E. S., Hafliðadóttir, S., et al. (2014) · Gastroenterology · doi:10.1016/s0016-5085(14)63307-2 · Cited by 144
Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism
Liu, Q., Yuan, B., Lo, K. A., Patterson, H. C., Sun, Y., & Lodish, H. F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211611109 · Cited by 144
Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery
Anty, R., Marjoux, S., Iannelli, A., Patouraux, S., Schneck, A.-S., Bonnafous, S., Gire, C., Amzolini, A. M., Amor, I. B., Saint‐Paul, M., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.014 · Cited by 143
Caffeine is protective in patients with non‐alcoholic fatty liver disease
Birerdinc, A., Stepanova, M., Pawloski, L. R., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04916.x · Cited by 143
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease
Pirola, C. J., Garaycoechea, M. E., Flichman, D., Arrese, M. A., Martino, J. S., Gazzi, C., Castaño, G. O., & Sookoian, S. C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p089953 · Cited by 142
Menopausal status and hepatic steatosis in a general female population
Völzke, H., Schwarz, S., Baumeister, S., Wallaschofski, H., Schwahn, C., Grabe, H.-J., Kohlmann, T., John, U., & Dören, M. (2007) · Gut · doi:10.1136/gut.2006.115345 · Cited by 141
Microbiota, NASH, HCC and the potential role of probiotics
Brandi, G., Lorenzo, S. D., Candela, M., Pantaleo, M. A., Bellentani, S., Tovoli, F., Saccoccio, G., & Biasco, G. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx007 · Cited by 141
Influence of Dietary Macronutrients on Liver Fat Accumulation and Metabolism
Parry, S. A., & Hodson, L. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000524 · Cited by 141
Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: a systematic review and meta-analysis
Smart, N. A., King, N., McFarlane, J. R., Graham, P. L., & Dieberg, G. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096197 · Cited by 140
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
McCommis, K. S., Hodges, W. T., Brunt, E. M., Nalbantoglu, I., McDonald, W. G., Holley, C. L., Fujiwara, H., Schaffer, J. E., Colca, J. R., & Finck, B. N. (2016) · Hepatology · doi:10.1002/hep.29025 · Cited by 139
Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher Propensity for NAFLD in men
Pramfalk, C., Pavlides, M., Banerjee, R., McNeil, C. A., Neubauer, S., Karpe, F., & Hodson, L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2649 · Cited by 138
Self-citation
Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission
Wild, S. H., Walker, J. J., Morling, J. R., McAllister, D., Colhoun, H. M., Farran, B., McGurnaghan, S. J., McCrimmon, R. J., Read, S. H., Sattar, N. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1590 · Cited by 138
The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis
Wettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 137
Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver
Schütte, K., Schulz, C., Poranzke, J., Antweiler, K., Bornschein, J., Bretschneider, T., Arend, J., Ricke, J., & Malfertheiner, P. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-117 · Cited by 136
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis
Pingitore, P., Dongiovanni, P., Motta, B. M., Meroni, M., Lepore, S. M., Mancina, R. M., Pelusi, S., Russo, C., Caddeo, A. M., Rossi, G. E., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw341 · Cited by 136
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
Honda, Y., Kessoku, T., Ogawa, Y., Tomeno, W., Imajo, K., Fujita, K., Yoneda, M., Takizawa, T., Saito, S., Nagashima, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42477 · Cited by 135
The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways
Fishman, P. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000008 · Cited by 132
Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women
Cox, C. L., Stanhope, K. L., Schwarz, J. M., Graham, J. L., Hatcher, B., Griffen, S. C., Bremer, A. A., Berglund, L., McGahan, J. P., Havel, P. J., et al. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2011.159 · Cited by 132
Nonalcoholic fatty liver disease and obstructive sleep apnea
Aron‐Wisnewsky, J., Clément, K., & Pépin, J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.004 · Cited by 129
Effect of Vildagliptin on Hepatic Steatosis
Macauley, M., Hollingsworth, K. G., Smith, F. E., Thelwall, P. E., Al-Mrabeh, A. H., Schweizer, A., Foley, J. E., & Taylor, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3794 · Cited by 126
Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism
Musso, G., Cassader, M., De Michieli, F., Rosina, F., Orlandi, F., & Gambino, R. (2012) · Hepatology · doi:10.1002/hep.25739 · Cited by 126
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
Lonardo, A., Ballestri, S., Guaraldi, G., Nascimbeni, F., Romagnoli, D., Zona, S., & Targher, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i44.9674 · Cited by 126
SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies
Liu, Z., Que, S., Zhou, L., & Zheng, S. (2015) · Scientific Reports · doi:10.1038/srep14325 · Cited by 125
Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
Nogueira, M. A., de Oliveira, C. P. M. S., Alves, V. A. F., Stefano, J. T., Rodrigues, L., Torrinhas, R. S., Cogliati, B., Barbeiro, H. V., Carrilho, F. J., & Waitzberg, D. L. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.05.001 · Cited by 123
The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage
Donati, B., Motta, B. M., Pingitore, P., Meroni, M., Pietrelli, A., Alisi, A., Petta, S., Xing, C., Dongiovanni, P., Menico, B. D., et al. (2015) · Hepatology · doi:10.1002/hep.28370 · Cited by 123
Fatty liver is an independent predictor of early carotid atherosclerosis
Pais, R., Giral, P., Khan, J.-F., Rosenbaum, D. H., Housset, C., Poynard, T., & Ratziu, V. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.023 · Cited by 123
The Effect of Hormone Replacement Therapy on Body Composition, Body Fat Distribution, and Insulin Sensitivity in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial
Sites, C. K., L’Hommedieu, G. D., Toth, M. J., Brochu, M., Cooper, B. C., & Fairhurst, P. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1479 · Cited by 122
A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
Jani, R. H., Pai, V., Jha, P. R., Jariwala, G., Mukhopadhyay, S., Bhansali, A. K., & Joshi, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0253 · Cited by 120
Body fat, metabolic syndrome and hyperglycemia in South Asians
Misra, A., Soares, M. J., Mohan, V., Shajith Anoop, S., Vishnu, A., Vaidya, R., & Pradeepa, R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.08.001 · Cited by 120
Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice
Rensen, S. S., Bieghs, V., Xanthoulea, S., Arfianti, E., Bakker, J. A., Shiri-Sverdlov, R., Hofker, M. H., Greve, J. W., & Buurman, W. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052411 · Cited by 116
Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL Production in NAFLD
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
Shiffman, M. L., Freilich, B. L., Vuppalanchi, R., Watt, K. D. S., Chan, J. L., Spada, A., Hagerty, D. T., & Schiff, E. R. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15030 · Cited by 115
Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus
Akuta, N., Kawamura, Y., Watanabe, C., Nishimura, A., Okubo, M., Mori, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., et al. (2018) · Hepatology Research · doi:10.1111/hepr.13304 · Cited by 114
Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?
Kumar, R. K., Rastogi, A., Sharma, M., Bhatia, V., Garg, H., Bihari, C., & Sarin, S. K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113758 · Cited by 113
Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial
Stefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., Hwang, J., Nowotny, P., KAHL, S., Harreiter, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70170-0 · Cited by 113
Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial
Bouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113
Histologic Spectrum of Nonalcoholic Fatty Liver Disease in Morbidly Obese Adolescents
Xanthakos, S. A., Miles, L., Bucuvalas, J. C., Daniels, S. R., García, V., & Inge, T. H. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00978-x · Cited by 110
Tissue-resident natural killer cells and their potential diversity
Sojka, D. K., Tian, Z., & Yokoyama, W. M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.010 · Cited by 109
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial
Spence, J. D., Viscoli, C. M., Inzucchi, S. E., Dearborn-Tomazos, J., Ford, G. A., Gorman, M., Furie, K. L., Lovejoy, A. M., Young, L. H., Kernan, W. N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0079 · Cited by 109
Inverse Association Between Serum Free Thyroxine Levels and Hepatic Steatosis: Results from the Study of Health in Pomerania
Ittermann, T., Haring, R., Wallaschofski, H., Baumeister, S. E., Nauck, M. A., Dörr, M., Lerch, M. M., zu Schwabedissen, H. E. M., Rosskopf, D., & Völzke, H. (2012) · Thyroid · doi:10.1089/thy.2011.0279 · Cited by 107
Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern
Wehmeyer, M. H., Zyriax, B., Jagemann, B., Roth, E., Windler, E. E. T., Wiesch, J. S. Z., Lohse, A. W., & Kluwe, J. (2016) · Medicine · doi:10.1097/md.0000000000003887 · Cited by 107
A 17‐Beta‐Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease
Yang, J., Trépo, E., Nahon, P., Cao, Q., Moreno, C., Letouzé, É., Imbeaud, S., Bayard, Q., Gustot, T., Deviere, J. M. E., et al. (2019) · Hepatology · doi:10.1002/hep.30623 · Cited by 107
Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy
Chan, R., Wong, V. W., Chu, C. W., Wong, G. L., Li, L. S., Leung, J. C. S., Chim, A. M., Yeung, D. K., Sea, M. M.-M., Woo, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139310 · Cited by 106
International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation
Tsochatzis, E., Coilly, A., Nadalin, S., Levistky, J., Tokat, Y., Ghobrial, M., Klinck, J., & Berenguer, M. (2019) · Transplantation · doi:10.1097/tp.0000000000002433 · Cited by 105
Efficacy of rosuvastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study
Nakahara, T., Hyogo, H., Kimura, Y., Ishitobi, T., Arihiro, K., Aikata, H., Takahashi, S., & Chayama, K. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01034.x · Cited by 103
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Ruzehaji, N., Frantz, C., Ponsoye, M., Avouac, J., Pezet, S., Guilbert, T., Luccarini, J., Broqua, P., Junien, J., & Allanore, Y. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208029 · Cited by 103
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?
Chin, J. L., Pavlides, M., Moolla, A., & Ryan, J. D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00159 · Cited by 103
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
Legry, V., Francque, S., Haas, J. T., Verrijken, A., Caron, S., Chávez‐Talavera, O., Vallez, E., Vonghia, L., Dirinck, E. L., Verhaegen, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01397 · Cited by 102

Flagged first, then by citations

4 of the 545 references couldn’t be matched to a known paper.

Research works printed but not linked: 41

Organization, 2014, Global Health Observatory (GHO) Data: Overweight and Obesity
Madrigal pharmaceuticals initiates phase 3, multinational, double-blind, randomized, placebo-controlled study of MGL-3196 (resmetirom) in patients with non-alcoholic steatohepatitis (NASH) and fibrosis to resolve NASH and reduce progression to cirrhosis a [press release]. Madrigal Pharmecueticals .2019, March 28. http://www.madrigalpharma.com/wp-content/uploads/2019/03/Madrigal-Pharmaceuticals-Initiates-Phase-3-NASH-Study.FINAL_.20190328.pdf. Accessed September 16, 2019.
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-Alcoholic Steatohepatitis, NCT02970942
A Study of Multiple Doses of HM15211 in Obese Subjects With NAFLD and in Subjects With NASH, NCT03744182
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients, NCT03205150
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR), NCT02855164
Phase 2b Study in NASH to Assess IVA337 (NATIVE), NCT03008070
Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH), NCT03676231
A Phase ll study of IMM-124E for Patients With Non-alcoholic Steatohepatitis, NCT02316717
Open-Label Study to Evaluate MN-001 on HDL and triglyceride in NASH & NAFLD Subjects, NCT02681055
Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects, NCT02673593
Safety and Efficacy Study of Orally Administered DS102 in Patients With NAFLD, NCT02941549
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH, NCT03166735
A Study to Evaluate the Safety, Tolerability and Efficacy of MSDC 0602K in Patients With NASH (EMMINENCE), NCT02784444
Fecal Microbiota Transplantation for the Treatment of Non-alcoholic Steatohepatitis (FMT-NASH), NCT03803540
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH): A Pilot Study, NCT02469272
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial, NCT02868164
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD), NCT03350165
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease, NCT03590626
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST), NCT03648554
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) Title, NCT02548351
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE), NCT03439254
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH), NCT02854605
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT), NCT02704403
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis (EVIDENCES IV), NCT03061721
AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH, NCT03028740
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH), NCT02443116
An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function, NCT03674476
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH), NCT03400163
A Study of Experimental Medication BMS-986036 Given to Healthy Participants, NCT03445208
A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH), NCT02413372
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes, NCT02097277
A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects, NCT03198182
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1), NCT03486899
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis, NCT03486912
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH), NCT02912260
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF), NCT02686762
Ratziu, 2018, One-year results of the global phase 2b randomized placebocontrolled ARREST trial of aramchol, a stearoyl CoA desaturase modulator in NASH patients, Hepatology., 68
Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD (FMT), NCT02496390
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis, NCT02721264
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease, NCT02927314

Sorted by citations

NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron‐Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.049 · Cited by 252
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
Rives, C., Fougerat, A., Ellero‐Simatos, S., Loiseau, N., Guillou, H., Gamet‐Payrastre, L., & Wahli, W. (2020) · Biomolecules · doi:10.3390/biom10121702 · Cited by 167
The role of NAD+ metabolism and its modulation of mitochondria in aging and disease
Yusri, K., Jose, S., Vermeulen, K. S., Tan, T. C. M., & Sorrentino, V. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00067-0 · Cited by 194

See all 228

Authors: Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W.
Affiliations: Churchill Hospital (GB)
John Radcliffe Hospital (GB)
Corresponding author: Tomlinson, Jeremy W
ORCID: Marjot, Thomas
Moolla, Ahmad
Cobbold, Jeremy F
Hodson, Leanne
Tomlinson, Jeremy W
Venue: Endocrine Reviews
Publisher: The Endocrine Society
Published: 2019-10-14
Volume: 41
Issue: 1
Pages: 66-117
ISSN: 0163-769X (ISSN-L)
1945-7189
DOI: 10.1210/endrev/bnz009
OpenAlex: W2980992948
Cited by: 228
References: 545
Citations by year: 2026: 12 · 2025: 35 · 2024: 25 · 2023: 46 · 2022: 53 · 2021: 29 · 2020: 23 · 2019: 3
FWCI: 3.94
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: Endocrine Reviews (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute for Health and Care Research
British Heart Foundation (FS/15/56/31645, FS/11/18/28633)
Department of Health and Social Care
University of Oxford
Novo Nordisk
Medical Research Council (MR/P011462/1)
Biotechnology and Biological Sciences Research Council (BBS/E/F/000PR10347)
NIHR Oxford Biomedical Research Centre
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, hepatic steatosis, liver fibrosis, liver cirrhosis, type 2 diabetes, obesity, hepatic lipid accumulation, liver inflammation, disease staging, non-invasive biomarkers, liver imaging, cardiovascular outcomes, metabolic outcomes, NAFLD therapy, adipose tissue, skeletal muscle
MeSH terms: Adult, Diabetes Mellitus, Type 2, Endocrinology, Humans, Liver, Liver Cirrhosis, Prognosis, Prevalence, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks